Introduction Hansoh Pharmaceutical ranks among the front-runners of innovative, research-focused pharmaceutical firms in China, dedicating its efforts to elevating human health through relentless innovation. Its strategic focus lies in the therapeutic areas of oncology, anti-infectives, central nervous system disorders, metabolic diseases, and autoimmune diseases. |
Disease Domain | Count |
---|---|
Neoplasms | 8 |
Endocrinology and Metabolic Disease | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 4 |
Small molecule drug | 2 |
Bispecific antibody | 2 |
Biological products | 2 |
Fusion protein | 1 |
Target |
Mechanism CD276 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACVR2A modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RANKL modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PM-1080 ( EGFR x c-Met ) | Non-squamous non-small cell lung cancer More | Phase 3 Clinical |
HS-20093 ( CD276 ) | Small Cell Lung Cancer More | Phase 3 |
Elritercept ( ACVR2A x TGF-β ) | myelodysplastic anemia More | Phase 2 |
HS-20089 ( B7-H4 ) | Primary peritoneal carcinoma More | Phase 2 |
HS-10384 | Hot Flashes More | Phase 2 |